Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. DrugBank Drug (Description in trials) KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1 Elranatamab
(B-CELL MATURATION ANTIGEN ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB)		[1] Elranatamab[1] Elranatamab 💬 [1] CD3E 💬 [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 28 💬
2 Linvoseltamab
(human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA)		[1] Linvoseltamab[1] Linvoseltamab 💬 [1] TNFRSF17 💬 [2] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production 💬[1] 28 💬
3 Mezagitamab
(Anti-Cd38 monoclonal antibody TAK-079)		[1] Mezagitamab[1] Mezagitamab 💬 [1] CD38 💬 [6] Calcium signaling pathway, Hematopoietic cell lineage, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬[2] 63, 66 💬
4 Muromonab
(Anti-CD3)		[1] ANTI-CD3[1] Muromonab-CD3 💬 [3] CD3D,
CD3E,
CD3G 💬 		[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[3] 60, 96, 97 💬
5 TNB-383B
(Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383)		[1] TNB-383B---[1] 28 💬